We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Last of the lot

17 September 2010 By Robert Cyran

The U.S. healthcare group may buy the remaining 82 percent of Crucell it doesn t own for $2.3 bln. Big Pharma has realized the value of vaccines, and Crucell is the last big independent player. The price is stiff, but it allows J&J to deploy cash stranded overseas.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)